Oncotelic Therapeutics, Inc. reports developments as a clinical-stage biopharmaceutical company focused on oncology, immunotherapy and rare-disease therapeutics. Company updates cover its internal drug pipeline, orphan oncology programs, antisense and small molecule injectable drug candidates, and partnerships or joint ventures used to license and co-develop selected candidates.
Recurring OTLC news also includes the PDAOAI AI platform for research, biomarker discovery, regulatory processes and GMP-compliant robotics, the company's 45% interest in GMP Bio and related Sapu Bio and Sapu Nano programs, and completed portfolio actions such as field-specific monetization of N2B nose-to-brain delivery assets.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Oncotelic Therapeutics (OTCQB:OTLC) announced the beta launch of its proprietary SEC chatbot, powered by DAO technology and AI, allowing users to engage with the Company's SEC filings as of April 12, 2023. Access to the chatbot is exclusive to holders of the Pet2DAO token (PDAO). The initiative aims to enhance shareholder engagement and streamline access to corporate information. Oncotelic's leadership expressed enthusiasm for the chatbot's potential, indicating plans for further innovations in AI and DAO functionalities. This aligns with Oncotelic's focus on leveraging advanced technologies to improve corporate governance and operations, particularly in the animal health sector. Interested users can access the chatbot through their website and are encouraged to provide feedback to enhance its capabilities.
Oncotelic Therapeutics (OTCQB:OTLC) has announced a strategic partnership with Vectara to leverage natural language understanding (NLU) technologies to enhance drug discovery and development in cancer, infectious disease, and aging.
The collaboration aims to streamline the research process by creating validated data corpora, making it easier for scientists to extract valuable insights from extensive research literature. This initiative seeks to accelerate the pace of pharmaceutical advancements and improve therapeutic outcomes.
Vectara's LLM-powered search and its innovative 'Grounded Generation' technology will be utilized to provide precise, relevant information, thus revolutionizing the application of AI in pharma research. Both companies anticipate significant advancements through this partnership.